Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

SGLT2 Inhibitors and Reducing the Risk of Cancers Among Diabetics , an Observational Study

NCT05612269 is registered in ClinicalTrials.gov with Ministry of Health, Saudi Arabia as lead sponsor.

NCT NCT05612269
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05612269 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
SGLT2 Inhibitors and Reducing the Risk of Cancers Among Diabetics , an Observational Study
Lead sponsor
Ministry of Health, Saudi Arabia
Phase
Observational
Overall status
Unknown status
Start date
September 1, 2022
Completion date
January 31, 2024
Enrollment
200 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cancer, diabetes mellitus, type 2, interleukin 6, sglt2 inhibitors